Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -1.48% | 348.37 | 0.0% | $6628.74m | |
| BNTX | BioNTech SE | 3.61% | 340.21 | 0.0% | $1132.49m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 3.71% | 10.91 | 0.7% | $762.65m | |
| NVAX | Novavax, Inc. | 3.48% | 185.56 | 79.8% | $671.59m | |
| AMGN | Amgen, Inc. | -0.56% | 240.19 | 1.3% | $496.45m | |
| BIIB | Biogen, Inc. | 1.86% | 332.79 | 1.7% | $439.25m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.54% | 198.47 | 1.9% | $408.33m | |
| GILD | Gilead Sciences, Inc. | 0.02% | 68.30 | 1.0% | $401.36m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.41% | 576.99 | 2.7% | $355.35m | |
| ILMN | Illumina, Inc. | -0.35% | 494.02 | 3.5% | $263.09m | |
| NTLA | Intellia Therapeutics, Inc. | -2.52% | 138.28 | 2.3% | $257.25m | |
| CRSP | CRISPR Therapeutics AG | 1.89% | 123.31 | 0.6% | $147.46m | |
| EXAS | EXACT Sciences Corp. | 1.24% | 109.17 | 18.1% | $125.11m | |
| XBIO | Xenetic Biosciences, Inc. | 20.40% | 4.90 | 0.0% | $123.02m | |
| SGEN | Seagen Inc. | 0.16% | 153.64 | 5.8% | $120.42m |
Company Profile
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.